Does Rallies show Form 4 insider transactions for BMRN?

Yes. Rallies tracks BMRN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is BMRN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BMRN. It does not provide personalized investment advice.

BMRN (BioMarin Pharmaceuticals Inc) Stock Analysis - Insider Trades

BioMarin Pharmaceuticals Inc (BMRN) is a publicly traded Healthcare sector company. As of May 20, 2026, BMRN trades at $52.02 with a market cap of $9.60B and a P/E ratio of 35.90. BMRN moved +0.76% today. Year to date, BMRN is -16.22%; over the trailing twelve months it is -16.16%. Its 52-week range spans $49.26 to $73.51. Analyst consensus is buy with an average price target of $89.31. Rallies surfaces BMRN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading BMRN stock inside the company?

Recent BMRN insider activity includes Friberg Gregory R sold 3.28K, Guyer Charles Greg sold 16.49K, Friberg Gregory R sold 6.33K, Davis George Eric sold 26.06K, and Burkhart Erin sold 1.79K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

BMRN Key Metrics

Key financial metrics for BMRN
Metric	Value
Price	$52.02
Market Cap	$9.60B
P/E Ratio	35.90
EPS	$1.40
Dividend Yield	0.00%
52-Week High	$73.51
52-Week Low	$49.26
Volume	1.84M
Avg Volume	0
Revenue (TTM)	$3.24B
Net Income	$268.74M
Gross Margin	76.53%

Recent BMRN Insider Trades

Friberg Gregory R sold 3.28K (~$176.68K) on May 7, 2026.
Guyer Charles Greg sold 16.49K (~$996.74K) on Mar 11, 2026.
Friberg Gregory R sold 6.33K (~$381.94K) on Feb 26, 2026.
Davis George Eric sold 26.06K (~$1.60M) on Feb 26, 2026.
Burkhart Erin sold 1.79K (~$105.93K) on May 20, 2025.

Latest BMRN News

BioMarin’s BMN 401 Raises PPi Through 52 Weeks but Misses RGI-C Endpoint — May 18, 2026
BioMarin slides as higher 2026 revenue outlook comes with lower EPS guidance — May 5, 2026
BioMarin’s VOXZOGO Yields 13.6 cm Height Gain and Stable Bone Density — May 2, 2026
BioMarin Completes $4.8B Amicus Acquisition, Adds Two Lysosomal Disease Therapies — Apr 28, 2026
BioMarin slides as Roctavian exit spotlights dependence on Voxzogo growth — Apr 12, 2026

BMRN Analyst Consensus

18 analysts cover BMRN: 0 strong buy, 13 buy, 5 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $89.31.

Common questions about BMRN

Who is trading BMRN stock inside the company?: Recent BMRN insider activity includes Friberg Gregory R sold 3.28K, Guyer Charles Greg sold 16.49K, Friberg Gregory R sold 6.33K, Davis George Eric sold 26.06K, and Burkhart Erin sold 1.79K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for BMRN?: Yes. Rallies tracks BMRN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is BMRN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BMRN. It does not provide personalized investment advice.